

## What we claim is:

1. A composition of matter comprising, as active agents, an adjuvant-effective amount of at least one sialidase and (2) an unrelated antigenic vaccine which gives rise to antibodies against an organism whose protal of entry, site of reproduction or site of disease causation is the mucosa, in a pharmaceutically acceptable carrier.

10

5

2. A composition of claim 1 wherein the carrier is a solid support.

4) 15 (1)

3. A composition of claim 1 which is a liquid.

15 (1)

A composition of claim 1 which is a powder.

20 || ||

5. A composition of claim 1 which is in capsule or tablet form.

6. A composition of claim 1 containing, additionally, anti-CD43 antibodies.

25

i za E

7. A composition of claim 1 which is a gel, a cream or a suppository.

30

8. A method of enhancing immune response in mammal by administration to the mucosa of an immune enhancing effective amount of sialidases in a pharmaceutically accepted carrier in conjunction with a antigenic vaccine.

9. A method of claim 8 wherein sialidase is administered in the form of drops or a spray.

35

10. A method of claim 8 wherein sialidase is administered in powder form.

- 11. A method of claim 8 wherein sialidase is administered on a solid support.
- 12. A method of claim 8 wherein sialidase is administered orally.
- 13. A method of claim 8 wherein sialidase is administered in animal feed.
- 10 14. A method of claim 8 wherein sialidase is administered in conjunction with an anti-CD4 antibody.
  - 15. A method of claim 14 wherein the anti-CD4 antibody is an anti-CD43 antibody.

5